

# About INOtherapy<sup>®</sup>

*INOtherapy<sup>®</sup> is a comprehensive suite of service and technologies designed to support the use of INOMAX<sup>®</sup>, the only naturally occurring signalling molecule in gas form that is FDA approved to treat newborns with hypoxic respiratory failure (HRF),<sup>1,2</sup> a potentially fatal condition in which infants are unable to transport enough oxygen from the air that they breathe.<sup>3</sup>*

## **Drug**

INOMAX, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension,<sup>4,5</sup> where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

By rapidly improving oxygenation, INOMAX may help reduce the amount of time patients require mechanical ventilation and respiratory support. Treatment with INOMAX reduces the need for extracorporeal membrane oxygenation, a highly invasive form of surgery that requires the use of a heart-lung machine.<sup>6</sup>

## **Drug Delivery Systems**

Delivering INOMAX requires a state-of-the-art medication management technology. The INOvent<sup>®</sup> delivery system is an FDA-cleared, bedside medical device that works in conjunction with a ventilator to deliver INOMax. More than 2,800 INOvent systems are in more than 700 US hospitals.<sup>7</sup> INOMAX also may be administered through the smaller, transportable INOMAX<sup>®</sup> DS unit.<sup>8</sup> INOMAX delivery technologies are compatible with numerous ventilation and respiratory strategies.

For INOtherapy customers, all drug delivery technology, equipment, and disposables are included. Accurate dosing, patient monitoring, and individualized record keeping are all part of the INOMAX experience.

## **Customer Service**

Behind INOtherapy is an extensive interdisciplinary team of clinical and logistical professionals who are on-call available 24/7/365.

Ikaria's regional customer service centers are located in or near Atlanta, Chicago, Dallas, Fremont (CA), Los Angeles, New York and Port Allen (LA). Clinical professionals can provide on-site training, education, and scientific and technical expertise to both new and existing INOtherapy customers.

## **Delivery Service**

To respond to immediate customer needs for either INOMax or the INOvent or INOMax DS drug-delivery systems, Ikaria owns and operates a national service that is able to respond to customer requests for on-site delivery anywhere in the US within four hours in most cases.

## Business Support

Information related to proper coding and billing, as well as coverage and reimbursement procedures is available to all customers.

## Safety

INOMax should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOMax may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO<sub>2</sub>) forms rapidly in gas mixtures containing nitric oxide and oxygen, and thus may cause airway inflammation and damage. Methemoglobin, NO<sub>2</sub>, and FiO<sub>2</sub> should be monitored during nitric oxide administration<sup>9</sup>.

Warning: The INOvent and INOMax DS Delivery Systems must only be used in accordance with the indications, usage, contraindications, warnings and precautions described in the nitric oxide drug package inserts and labeling.

For more information on INOMax and its delivery devices, including important safety information and full prescribing information, please visit [www.inomax.com](http://www.inomax.com).

### References:

1. INOMax website. What is INOMax? Available at <http://www.inomax.com/overview.html>. Accessed January 28, 2009. [P1, C1, L1 –2].
2. PEDIATRICS Journal website. Cost Effectiveness of Inhaled Nitric Oxide in the Treatment of Neonatal Respiratory Failure in the United States. Available at <http://pediatrics.aappublications.org/cgi/content/abstract/112/6/1351>. Accessed January 30, 2009. Angus, Clermont, Watson, et.al. 2003. [P2, C1, L55 –68].
3. National Institutes of Health website. Inhaled Treatment Effective for Hypoxic Respiratory Failure in Newborns. Available at <http://www.nih.gov/news/pr/feb97/nichd-26.htm>. Accessed April 20<sup>th</sup>, 2009. Robert Bock, 1997. [P3, C1, L27 –28].
4. INOMax website. Prescribing and Safety Information page. Available at <http://www.inomax.com/prescribing-information.html>. Accessed January 30, 2009. [P1, C1, L1 – 4]
5. NEJM website. Inhaled Nitric Oxide in Full-Term and Nearly Full-Term Infants with Hypoxic Respiratory Failure. Available at <http://content.nejm.org/cgi/content/full/336/9/597>. Accessed January 30, 2009. Ehrenkranz, Finer, et.al. 1997. [P10, C1, L401–403]
6. Ehrenkranz, Finer, et.al. 1997. [P7, C1, L280 –284].
7. Records on file, Ikarria Holdings
8. INOMax website. Drug Delivery Devices page. Available at <http://www.inomax.com/setup.html>. Accessed January 30, 2009. [P1, C1, L32 –36]
9. INOMax website. Prescribing and Safety Information page. Accessed January 30, 2009. [P1, C1, L10-11, 18 – 19]